[go: up one dir, main page]

WO1999059499A3 - Serotonergic 5ht7 receptor compounds for treating ocular and cns disorders - Google Patents

Serotonergic 5ht7 receptor compounds for treating ocular and cns disorders Download PDF

Info

Publication number
WO1999059499A3
WO1999059499A3 PCT/US1999/010179 US9910179W WO9959499A3 WO 1999059499 A3 WO1999059499 A3 WO 1999059499A3 US 9910179 W US9910179 W US 9910179W WO 9959499 A3 WO9959499 A3 WO 9959499A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
serotonergic
cns disorders
disorders
treating ocular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/010179
Other languages
French (fr)
Other versions
WO1999059499A2 (en
Inventor
Jesse A May
Thomas R Dean
Najam A Sharif
Hwang-Hsing Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Vision LLC
Original Assignee
Alcon Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BR9910590-0A priority Critical patent/BR9910590A/en
Priority to CA002332505A priority patent/CA2332505A1/en
Priority to US09/674,403 priority patent/US6960579B1/en
Priority to EP99922894A priority patent/EP1079763A2/en
Priority to AU39788/99A priority patent/AU3978899A/en
Priority to JP2000549166A priority patent/JP2002515408A/en
Application filed by Alcon Laboratories Inc filed Critical Alcon Laboratories Inc
Publication of WO1999059499A2 publication Critical patent/WO1999059499A2/en
Publication of WO1999059499A3 publication Critical patent/WO1999059499A3/en
Anticipated expiration legal-status Critical
Priority to US11/100,918 priority patent/US7060704B2/en
Priority to US11/265,030 priority patent/US7285553B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Compounds with 5HT7 receptor affinity (some of which are novel) useful for lowering IOP, improving blood flow to the optic nerve head and the retina, providing neuroprotection, and treating retinal diseases are disclosed. The Compounds are also useful for treating sleep disorders, depression, and other psychiatric disorders, such as, schizophrenia, anxiety, obsessive compulsive disorder, circadian rhythm disorders, and centrally and peripherally mediated hypertension. Compositions and methods for their use are also disclosed.
PCT/US1999/010179 1998-05-19 1999-05-10 Serotonergic 5ht7 receptor compounds for treating ocular and cns disorders Ceased WO1999059499A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA002332505A CA2332505A1 (en) 1998-05-19 1999-05-10 Serotonergic 5ht7 receptor compounds for treating ocular and cns disorders
US09/674,403 US6960579B1 (en) 1998-05-19 1999-05-10 Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
EP99922894A EP1079763A2 (en) 1998-05-19 1999-05-10 Serotonergic 5ht 7? receptor compounds for treating ocular and cns disorders
AU39788/99A AU3978899A (en) 1998-05-19 1999-05-10 Serotonergic 5HT, receptor compounds for treating ocular and CNS disorders
JP2000549166A JP2002515408A (en) 1998-05-19 1999-05-10 Serotonergic 5HT7 receptor compounds for the treatment of ocular and central nervous system disorders
BR9910590-0A BR9910590A (en) 1998-05-19 1999-05-10 Compound, process to decrease iop, to improve blood flow to the end of the optic nerve and the retina, and to treat retinal diseases, compositions to decrease iop, to improve blood flow to the end of the optic nerve and the retina, and to treating retinal diseases, process and composition to provide neuroprotection to the end of the optic nerve or the retina, and, process to treat people suffering from sleep disorders, depression, schizophrenia, anxiety, circadian rhythmic disorders and centrally and peripherally mediated hypertension
US11/100,918 US7060704B2 (en) 1998-05-19 2005-04-07 Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
US11/265,030 US7285553B2 (en) 1998-05-19 2005-11-02 Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US8598998P 1998-05-19 1998-05-19
US8600598P 1998-05-19 1998-05-19
US8600698P 1998-05-19 1998-05-19
US8600298P 1998-05-19 1998-05-19
US60/086,002 1998-05-19
US60/086,006 1998-05-19
US60/086,005 1998-05-19
US60/085,989 1998-05-19

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09674403 A-371-Of-International 1999-05-10
US11/100,918 Division US7060704B2 (en) 1998-05-19 2005-04-07 Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders

Publications (2)

Publication Number Publication Date
WO1999059499A2 WO1999059499A2 (en) 1999-11-25
WO1999059499A3 true WO1999059499A3 (en) 2000-03-16

Family

ID=27491993

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/010179 Ceased WO1999059499A2 (en) 1998-05-19 1999-05-10 Serotonergic 5ht7 receptor compounds for treating ocular and cns disorders

Country Status (7)

Country Link
EP (1) EP1079763A2 (en)
JP (1) JP2002515408A (en)
CN (1) CN1301161A (en)
AU (1) AU3978899A (en)
BR (1) BR9910590A (en)
CA (1) CA2332505A1 (en)
WO (1) WO1999059499A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6956036B1 (en) 2000-03-17 2005-10-18 Alcon, Inc. 6-hydroxy-indazole derivatives for treating glaucoma
US7005443B1 (en) 2000-03-17 2006-02-28 Alcon, Inc. 5-Hydroxy indazole derivatives for treating glaucoma

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
GB9828004D0 (en) * 1998-12-18 1999-02-10 Smithkline Beecham Plc Use
AU4856600A (en) 1999-05-18 2000-12-05 Synaptic Pharmaceutical Corporation Use of agonists or antagonists of the 5-ht7 receptor to treat disorders of the bladder
PL358481A1 (en) * 2000-03-17 2004-08-09 Alcon Inc. 6-hydroxy-indazole derivatives for treating glaucoma
AU1918001A (en) * 2000-03-17 2001-10-03 Alcon Universal Ltd 5-hydroxy indazole derivatives for treating glaucoma
US6630469B2 (en) 2000-05-09 2003-10-07 Bristol-Myers Squibb Company 5-HT7 receptor antagonists
TW593302B (en) 2001-12-20 2004-06-21 Alcon Inc Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
AU2003300915B2 (en) 2002-12-13 2008-08-28 Alcon, Inc. Novel benzopyran analogs and their use for the treatment of glaucoma
AR046890A1 (en) 2003-12-15 2005-12-28 Alcon Inc [1,4] OXAZINO [2,3-G] SUBSTITUTED INDAZOLS FOR THE TREATMENT OF GLAUCOMA.
US7129257B1 (en) 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
US7425572B2 (en) 2004-12-08 2008-09-16 Alcon, Inc. Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880134A (en) * 1996-03-20 1999-03-09 Eli Lilly And Company Method for using ergoline compounds to effect physiological and pathological functions at the 5-HT7 receptor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880134A (en) * 1996-03-20 1999-03-09 Eli Lilly And Company Method for using ergoline compounds to effect physiological and pathological functions at the 5-HT7 receptor

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6956036B1 (en) 2000-03-17 2005-10-18 Alcon, Inc. 6-hydroxy-indazole derivatives for treating glaucoma
US7005443B1 (en) 2000-03-17 2006-02-28 Alcon, Inc. 5-Hydroxy indazole derivatives for treating glaucoma

Also Published As

Publication number Publication date
WO1999059499A2 (en) 1999-11-25
BR9910590A (en) 2001-01-23
CA2332505A1 (en) 1999-11-25
JP2002515408A (en) 2002-05-28
EP1079763A2 (en) 2001-03-07
AU3978899A (en) 1999-12-06
CN1301161A (en) 2001-06-27

Similar Documents

Publication Publication Date Title
WO1999059499A3 (en) Serotonergic 5ht7 receptor compounds for treating ocular and cns disorders
WO2003051315A3 (en) Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5
CA2469813A1 (en) Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
GR3035372T3 (en) Tachykinin antagonists.
WO2003053922A3 (en) Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5
PT1235787E (en) BETA2 ADRENERGIC AGONISTIC RECEPTORS
DE69429717D1 (en) HETEROCYCLIC COMPOUNDS AND THEIR PRODUCTION AND USE
CA2243234A1 (en) 5h-thiazolo[3,2-a]pyrimidine derivatives
NO905253L (en) PROCEDURE FOR THE PREPARATION OF SUBSTITUTED CYCLOHEXANOLS.
WO2002066469A3 (en) Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands
WO2007016155A3 (en) Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
SG157231A1 (en) Substituted p-diaminobenzene derivatives
CA2521648C (en) Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof
EP1110554A4 (en) MEDICINAL COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES
CA2498291A1 (en) Diazabicyclic compounds useful in the treatment of cns and other disorders
AU8160194A (en) Ophthalmic suspension containing diflupredonate
WO2004030629A3 (en) Novel neurokinin antagonists and methods of use thereof
EP1280781A4 (en) 5-ht 7 receptor antagonists
NO176097C (en) Analogous process for the preparation of therapeutically active substituted cyclohexenes
BR0314459A (en) Method for lowering and controlling intraocular pressure and / or for the treatment of mammals suffering from glaucoma and compost.
PT1254905E (en) 4- (2-PYRIDYL) PIPERIZINES HAVING AGRONIST ACTIVITY OF 5HT7 RECEPTOR
WO2003037260A3 (en) Methods and compositions for treating parkinson's disease
UY24717A1 (en) NEW TREATMENT
MXPA03001160A (en) Method of treating neurodegenerative disorders of the retina and optic nerve head.
WO2003051291A3 (en) Substituted 5-hydroxy-indole compounds for the treatment of glaucoma

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99806330.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR CA CN JP MX US ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU BR CA CN JP MX US ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 09674403

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/011211

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2332505

Country of ref document: CA

Ref document number: 2000 549166

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200006715

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 39788/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999922894

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999922894

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999922894

Country of ref document: EP